KDR and neoplasm: Therefore, monoclonal antibodies and small molecule tyrosine kinase inhibitors that target the VEGF/VEGFR pathway, such as Bevacizumab, Ranibizumab, Sorafenib, and Sunitinib, present promising strategies for anti-tumor treatment.